PTO Lobbies Against Damages Award Provision in Patent Reform Bill
Executive Summary
The U.S. Patent and Trademark Office has launched a full court press to get the Senate Judiciary Committee to revise its patent reform bill
You may also be interested in...
Patent Reform Provision Extending Angiomax Patent Would Cost $1 Bil. – CBO
The Medicines Company scored a lobbying victory when a provision was tucked into patent reform legislation that would authorize the Patent and Trademark Office to accept late applications
Patent Reform Provision Extending Angiomax Patent Would Cost $1 Bil. – CBO
The Medicines Company scored a lobbying victory when a provision was tucked into patent reform legislation that would authorize the Patent and Trademark Office to accept late applications
Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits